Europese Unie - IJslands - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Æxlishemjandi lyf - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Europese Unie - IJslands - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Europese Unie - IJslands - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - eitilfrumukrabbamein, mantle-cell - Æxlishemjandi lyf - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Europese Unie - IJslands - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Europese Unie - IJslands - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 og 5.

Europese Unie - IJslands - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - einstofna mótefni - Áður ómeðhöndlað langvarandi eitilfrumuhvítblæði (cll): arzerra ásamt klórambúcíl eða bendamustine er ætlað fyrir sjúklinga með cll sem hafa ekki fengið áður en meðferð og hver ert ekki hæf til flúdarabín byggir meðferð. fallið cll: arzerra er ætlað ásamt flúdarabín og cýklófosfamíði fyrir meðferð fullorðinn sjúklinga með fallið cll. svarar cll: arzerra er ætlað fyrir meðferð cll í sjúklingum sem svarar til flúdarabín og alemtuzumab.

Europese Unie - IJslands - EMA (European Medicines Agency)

alexion europe sas - sebelipasa alfa - lipid efnaskipti, innfelldar villur - Önnur meltingarvegi og efnaskipti vörur, - kanuma er ætlað til langtímameðferð með ensímuppbótarmeðferð (ert) hjá sjúklingum á öllum aldri, með skort á lysósölt sýru lípasa (lal).

Europese Unie - IJslands - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

Europese Unie - IJslands - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - til að draga úr lengd mæði í tengslum og tíðni hita og mæði í tengslum vegna lyfjameðferð.

Europese Unie - IJslands - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - litlaræxli - Æxlishemjandi lyf - meðferð við krabbameini í ristli með endaþarmi (mcrc).